Brain shuttle peptides derived from phage display.
Brain shuttle peptides are making waves in research thanks to phage display. Researchers at Rutgers have been using this technique to screen massive libraries of peptides and find those rare hits that can actually cross the blood-brain barrier (BBB). Forget the old days of trial-and-error. Phage display exploits the unique molecular landscape of brain vasculature, unlocking new ways to deliver compounds where most can’t go.
Adv Pharmacol
by Ille AM, Tang FHF, Chen ER et al.
“Brain shuttle peptides derived from phage display. Ille AM(1), Tang FHF(1), Chen ER(1), Arap W(2), Pasqualini R(3). Author information: (1)Rutgers Cancer Institute, Newark, NJ, United States; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ, United States. (2)Rutgers Cancer Institute, Newark, NJ, United States; Division of Hematology/Oncology, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, United States. Electronic address: wadih.arap@rutgers.edu. (3)Rutgers Cancer Institute, Newark, NJ, United States; Division of Cancer Biology, Department of Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ, United States. Electronic address: renata.pasqualini@rutgers.edu. Vascular beds within different tissues, including the brain, exhibit diverse molecular heterogeneity. Screening of peptide libraries using in vivo phage display exploits this heterogeneity, enabling the discovery of peptide ligands which selectively home to specific tissues. A prime example is identification of the iron-mimicking peptide CRTIGPSVC which undergoes receptor-mediated transport across the blood-brain barrier (BBB) by binding to the transferrin/transferrin receptor (TfR) complex. Various other brain-homing and BBB-crossing peptides have been discovered by in vivo phage display as well as phage display performed in vitro, i.e., in BBB models, cultured cells, and immobilized receptors. Furthermore, these peptides have been used for preclinical therapeutic applications for a number of different brain disorders. Continued research involving phage display is expected to further characterize the determinants of BBB transport, uncover additional BBB-crossing peptides, and facilitate ongoing development of brain-targeted therapies. Copyright © 2026. Published by Elsevier Inc.”
Key finding: The peptide CRTIGPSVC mimics iron and binds the transferrin/transferrin receptor complex. That’s the ticket for receptor-mediated transport across the BBB. In plain English, it hitches a ride into the brain by hijacking the same pathway iron uses. This is just one example—researchers have identified several BBB-crossing and brain-homing peptides using both in vivo and in vitro phage display methods.
Why does this matter? The BBB has been a major roadblock for studying and treating brain disorders. Most large molecules can’t cross it, which means new tools are needed. Brain shuttle peptides open doors for research into:
Drug delivery systems designed to reach the brain
Preclinical models for neurological disease
Diagnostics targeting brain tissues
Phage display isn’t just limited to live animal models. It’s also being used in cell cultures and with isolated BBB receptors, speeding up discovery. This points to a future with more precise, tissue-specific peptides and better-controlled research.
For researchers, these advances are a big deal. The more we understand about BBB transport, the faster we can develop and test new brain-targeted approaches. If you want more context on peptide discovery and applications, check the peptide research index.
Brain shuttle peptides are changing the game for brain research. The field is just getting started.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.